Dapagliflozin (Standard)

Overview

Dapagliflozin (Standard) is the analytical standard of Dapagliflozin. This product is intended for research and analytical applications. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 ( SGLT2 ) inhibitor, which results in excretion of glucose into the urine. Dapagliflozin induces HIF1 expression and attenuates renal IR injury.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Others | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cancer | Products > Signaling Pathways > Reference Standards | Products > Signaling Pathways > SGLT

Product Information

• Catalog No.: HY-10450R
• CAS No.: 461432-26-8
• Molecular Formula: C21H25ClO6
• Molecular Weight: 408.87
• Purity: 99.96%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source